Omeros (NASDAQ:OMER) has earned a consensus rating of “Hold” from the eleven analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $26.43.
OMER has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Bank of America upped their price target on shares of Omeros from $2.44 to $4.00 in a report on Wednesday, February 14th. HC Wainwright set a $30.00 price target on shares of Omeros and gave the stock a “buy” rating in a report on Monday, February 19th. ValuEngine upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, WBB Securities reiterated a “buy” rating and set a $75.00 price target on shares of Omeros in a report on Monday, March 26th.
Several large investors have recently made changes to their positions in the company. Mesirow Financial Investment Management Inc. increased its holdings in shares of Omeros by 35.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 18,808 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 4,940 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Omeros by 13.8% in the third quarter. Wells Fargo & Company MN now owns 42,144 shares of the biopharmaceutical company’s stock worth $911,000 after purchasing an additional 5,102 shares during the last quarter. Baird Financial Group Inc. grew its stake in shares of Omeros by 9.0% in the fourth quarter. Baird Financial Group Inc. now owns 62,296 shares of the biopharmaceutical company’s stock worth $1,210,000 after purchasing an additional 5,151 shares during the last quarter. Teachers Advisors LLC grew its stake in shares of Omeros by 7.1% in the fourth quarter. Teachers Advisors LLC now owns 80,820 shares of the biopharmaceutical company’s stock worth $1,570,000 after purchasing an additional 5,355 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. bought a new stake in shares of Omeros in the fourth quarter worth $106,000. Institutional investors own 48.51% of the company’s stock.
OMER traded down $0.22 during trading on Wednesday, hitting $13.96. 410,939 shares of the stock traded hands, compared to its average volume of 1,339,025. Omeros has a twelve month low of $8.36 and a twelve month high of $27.09. The company has a market cap of $684.70, a P/E ratio of -17.68 and a beta of 3.61. The company has a debt-to-equity ratio of -29.93, a current ratio of 4.12 and a quick ratio of 4.10.
Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The business had revenue of $13.76 million for the quarter, compared to analyst estimates of $21.94 million. During the same period in the prior year, the company posted ($0.45) EPS. Omeros’s quarterly revenue was up 6.7% on a year-over-year basis. analysts expect that Omeros will post -1.51 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Omeros (OMER) Receives Average Rating of “Hold” from Brokerages” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://transcriptdaily.com/2018/04/16/omeros-omer-receives-average-rating-of-hold-from-brokerages.html.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.